Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficiency of Anti-CD19/CD22 CAR-T in Pediatric/Young Adult R/R B-ALL
NCT04499573Phase 2Active, not recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR-T19/CAR-T22 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Started Jul 2020; status: active, not recruiting.
02
Drugs
CAR-T19/CAR-T22
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04499573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499573.